Amgen has partnered with Humana to improve health outcomes and efficiency by tapping into new insights from the US health insurer’s 13 million members.
Initially targeting multiple conditions, including cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer, researchers will combine real world evidence with data from wearable technology, digital apps and Bluetooth-enabled drug delivery services.
The research will identify patients whose medical conditions are likely to result in an adverse patient outcome, which may lead to development of algorithms that can predict risk and drive to early intervention.
Laura Happe, chief pharmacy officer at Humana, said: “Humana is focused on the holistic health of our members and by teaming up with Amgen we can study new ways to improve the health outcomes for our members.
“At the same time, we hope this research results in new tools and technology that support our provider partners who are on the journey to population health and value-based care.”
The collaboration will see the duo undertake six projects to deliver increased value to patients by focusing on improving quality and outcomes regarding health care costs.
Joshua Ofman, Amgen‘s senior vice president of global value, access and policy, said: “The rising cost of disease is challenging the sustainability of our health care system in the US and is motivating innovators to urgently develop new therapeutic options and partner on opportunities to reduce financial burden to the system.”
The partnership will also look into specific therapeutic areas including defining the burden of osteoporatic fractures to understanding the impact and wearable technology on medication adherence for inflammatory diseases.
More projects are expected over the term of the agreement, with prospective observational studies planned.
